TIAA CREF Investment Management LLC cut its stake in Immunomedics, Inc. (NASDAQ:IMMU) by 4.5% during the first quarter, Holdings Channel reports. The institutional investor owned 265,786 shares of the biopharmaceutical company’s stock after selling 12,464 shares during the period. TIAA CREF Investment Management LLC’s holdings in Immunomedics were worth $1,720,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in IMMU. Quantitative Systematic Strategies LLC acquired a new stake in Immunomedics during the first quarter valued at approximately $137,000. Metropolitan Life Insurance Co. NY raised its stake in Immunomedics by 3.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 66,049 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 2,384 shares in the last quarter. American International Group Inc. raised its stake in Immunomedics by 17.8% in the first quarter. American International Group Inc. now owns 59,094 shares of the biopharmaceutical company’s stock valued at $382,000 after buying an additional 8,910 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Immunomedics during the first quarter valued at approximately $383,000. Finally, UBS Asset Management Americas Inc. raised its stake in Immunomedics by 361.2% in the first quarter. UBS Asset Management Americas Inc. now owns 67,301 shares of the biopharmaceutical company’s stock valued at $435,000 after buying an additional 52,709 shares in the last quarter. Institutional investors and hedge funds own 62.10% of the company’s stock.

Immunomedics, Inc. (IMMU) opened at 8.20 on Thursday. The firm has a 50-day moving average of $8.65 and a 200-day moving average of $6.76. The stock’s market capitalization is $898.75 million. Immunomedics, Inc. has a 12-month low of $2.02 and a 12-month high of $9.51.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/10/tiaa-cref-investment-management-llc-sells-12464-shares-of-immunomedics-inc-immu.html.

IMMU has been the topic of several recent research reports. BidaskClub lowered shares of Immunomedics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Jefferies Group LLC set a $8.00 price objective on shares of Immunomedics and gave the stock a “buy” rating in a research report on Thursday, April 20th. Zacks Investment Research upgraded shares of Immunomedics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research report on Monday, July 17th. ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Cowen and Company restated an “outperform” rating and issued a $15.00 target price on shares of Immunomedics in a report on Monday, July 24th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Immunomedics presently has a consensus rating of “Buy” and an average target price of $12.00.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.